Specific block of androgen receptor activity by antisense oligonucleotides

F Hamy1, V Brondani, R Spoerri

  • 1Novartis AG, Pharma Research, Oncology Department, Basel, Switzerland. francois.hamy@unibas.ch

Insights

Researchers developed targeted antisense oligonucleotides to inhibit androgen receptor (AR) expression in prostate cancer cells. This approach effectively reduced AR activity and showed potential for in vivo cancer treatment.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • Prostate cancer cells can develop resistance to anti-hormone therapies.
  • This resistance is linked to hormone-independent activation of the androgen receptor (AR).
  • Understanding AR's role is crucial for developing new treatment strategies.

Purpose of the Study:

  • To investigate the hypothesis of AR's role in anti-hormone resistance.
  • To develop and test antisense oligonucleotides targeting AR mRNA expression.
  • To evaluate the efficacy of these oligonucleotides in inhibiting AR activity.

Main Methods:

  • Synthesized 49 antisense oligonucleotides targeting different regions of AR mRNA.
  • Tested oligonucleotides in a cellular AR-dependent reporter system.
  • Validated potent inhibitors using point-mutated controls and assessed AR-driven gene expression (PSA).

Main Results:

  • Identified five highly potent antisense oligonucleotides inhibiting AR-driven gene expression.
  • Demonstrated specific shutdown of hormone-independent AR transactivation by IGF-1.
  • Confirmed AR inhibition in the LNCaP prostate cancer cell line.

Conclusions:

  • Targeted antisense oligonucleotides effectively inhibit AR expression and activity.
  • These tools are valuable for studying the central role of AR in prostate cancer growth.
  • Potential therapeutic utility in vivo for prostate cancer treatment.

Related Concept Videos

RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...